바로가기메뉴

본문 바로가기 주메뉴 바로가기

Tuberculosis & Respiratory Diseases

Article Contents

Prev Next
e-Submission

Vol.59 No.2
Citation Share

The effect of Combination Therapy of Inhaled Corticosteroids and Long-acting Beta2-agonists on Acute Exacerbation in Moderate to Severe COPD Patients

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2005, v.59 no.2, pp.164-169
















& (2005). The effect of Combination Therapy of Inhaled Corticosteroids and Long-acting Beta2-agonists on Acute Exacerbation in Moderate to Severe COPD Patients. Tuberculosis & Respiratory Diseases, 59(2), 164-169.
  • Downloaded
  • Viewed
PDF Download

Abstract

Background : The role of combination therapy of inhaled corticosteroid (ICS) plus long-acting β2-agonist (LABA) in asthma is well established, but nor much is known about this treatment in COPD. Recent studies have revealed that combining therapy is associated with fewer acute exacerbations in COPD, but in most of the studies, high-dose combination therapies have been employed. The current study assessed the effect of moderate or high-dose combination therapy of ICS plus LABA on the frequency of acute exacerbations in COPD. Methods : Between January 1, 2001 and August 31, 2004, 46 patients with COPD (moderate, severe, very severe) were enrolled who received either fluticasone/salmeterol (flu/sal) 250μg /50μg twice a day (group A) or flu/sal 500μg /50μg twice a day (group B) for more than a year. We divided them into two groups depending on the dosage of ICS plus LABA. Effect of drugs was compared based on the factors such as symptom aggravation, number of admission, and time to first exacerbation during a year after use. Results : Eleven of twenty-six patients in group A (42.3%) experienced acute exacerbation and eleven of twenty patients in group B (55%) experienced acute exacerbation during 1 year. Mean exacerbation rate of Group A was 0.96 and Group B was 1.05. Mean admission rate was 0.15 and 0.30, respectively. There was no statistically significant difference of aggravation rate, number of administration and time to first exacerbation between the two treatment groups. Conclusion : There was no significant difference between moderate and high dose combined inhaler therapy to reduce acute exacerbation in COPD patients (moderate, severe, very severe). Hence, the effective dose of combination therapy needs further study in patients with COPD. (Tuberc Respir Dis 2005; 59: 164-169)

keywords
COPD, Acute exacerbation, Inhaled corticosteroids, Long acting β2-agonist, COPD, Acute exacerbation, Inhaled corticosteroids, Long acting β2-agonist

Reference

1.

(2004) Prevalence of COPD in Koreans,

2.

(2004) Global strategy for the diagnosis management and prevention of chronic obstructive pulmonary disease,

3.

(2000) Chronic obstructive pulmonary disease,

4.

(2004) Management of chronic obstructive pulmonary disease,

5.

(2003) Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease,

6.

(2003) Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease:a randomized controlled trial,

7.

(2003) Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease,

8.

(2003) Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease:a meta- analysis,

9.

(2003) Inhaled corticosteroids in chronic obstructive pulmonary disease and risk of death and hospitalization,

10.

(2004) Inhaled corticosteroids and the risk of a first exacerbation in COPD patients,

11.

(2004) is there light at the end of the tunnel ?,

12.

(2004) The nature of small-airway obstruction in chronic obstructive pulmonary disease,

13.

(2004) Mediators of chronic obstructive pulmonary disease,

14.

(2004) Corticosteroid resistance in chronic obstructive pulmonary disease:inactivation of histone deacetylase,

15.

(2003) Salmeterol & fluticasone 50 microg/250 microg bid in combination provides a better long-term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophylline,

16.

(2004) Inhaled combination therapy with long-acting beta 2-agonists and corticosteroids in stable COPD,

17.

(2003) Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease:a meta-analysis,

18.

(2003) Inhaled corticosteroids and survival in chronic obstructive pulmonary disease,

Tuberculosis & Respiratory Diseases

e-Submission OA Policy